Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dramatic response to high-dose icotinib in a lung adenocarcinoma patient after erlotinib failure.

Lung cancer (Amsterdam, Netherlands) - 1 Feb 2014

Guan Yin, Zhao Hong, Meng Jing, Yan Xiang, Jiao ShunChang

Abstract excerpt

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) retreatment is rarely administered for non-small cell lung cancer (NSCLC) patients who did not respond to previous TKI treatment. A high dose of TKI may overcome resistance to the standard dose of TKI and have different effec...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cisplatin
Share to Crown Ethers
Share to Docetaxel

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Dosage Calculations

Share to Erlotinib Hydrochloride

Share to Remission Induction

Share to Salvage Therapy

Share to Taxoids

Source

Identifiers

PMID: 24370197
DOI: 10.1016/j.lungcan.2013.12.002

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24370197-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dramatic response to high-dose icotinib in a lung adenocarcinoma patient after erlotinib failure.PMID 24370197Read ↗

Effective treatment with icotinib in advanced lung adenocarcinoma harboring rare EGFR mutation G719A/L833V: A case report.Semantic proximity Read ↗

A Phase I Study of the Safety and Pharmacokinetics of Higher-Dose Icotinib in Patients With Advanced Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Icotinib, an Effective Treatment Option for Patients With Lung Adenocarcinoma Harboring Compound EGFR L858R and A871G MutationSemantic proximity Read ↗

Retrospective analysis of icotinib neoadjuvant therapy of 63 lung cancer patients.Semantic proximity Read ↗

Efficacy and influence factors of icotinib hydrochloride in treating advanced non-small cell lung cancer.Semantic proximity Read ↗

Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Icotinib: efficacy in different solid tumors and gene mutations.Semantic proximity Read ↗

[Clinical Observation of Icotinib Hydrochloride for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified].Semantic proximity Read ↗

New EGFR-TKI: a case report of recurrent lung adenocarcinoma successfully treated with icotinib.Semantic proximity Read ↗

Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer.Semantic proximity Read ↗

Successful salvage therapy using high-dose furmonertinib (AST2818) for non-small-cell lung cancer after Osimertinib resistance: a case report.Semantic proximity Read ↗

[Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.